|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PCGF2 |
Gene summary for PCGF2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PCGF2 | Gene ID | 7703 |
| Gene name | polycomb group ring finger 2 | |
| Gene Alias | MEL-18 | |
| Cytomap | 17q12 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R1V6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7703 | PCGF2 | GSM4909290 | Human | Breast | IDC | 3.64e-33 | 7.56e-01 | 0.2096 |
| 7703 | PCGF2 | GSM4909292 | Human | Breast | IDC | 2.42e-08 | 6.83e-01 | 0.1236 |
| 7703 | PCGF2 | GSM4909293 | Human | Breast | IDC | 1.40e-42 | 7.70e-01 | 0.1581 |
| 7703 | PCGF2 | GSM4909311 | Human | Breast | IDC | 5.25e-04 | 1.94e-03 | 0.1534 |
| 7703 | PCGF2 | GSM4909319 | Human | Breast | IDC | 5.37e-07 | 8.84e-03 | 0.1563 |
| 7703 | PCGF2 | DCIS2 | Human | Breast | DCIS | 8.24e-29 | 9.83e-02 | 0.0085 |
| 7703 | PCGF2 | P2T-E | Human | Esophagus | ESCC | 1.51e-22 | 3.98e-01 | 0.1177 |
| 7703 | PCGF2 | P4T-E | Human | Esophagus | ESCC | 1.24e-11 | 3.20e-01 | 0.1323 |
| 7703 | PCGF2 | P5T-E | Human | Esophagus | ESCC | 1.46e-06 | 1.60e-01 | 0.1327 |
| 7703 | PCGF2 | P8T-E | Human | Esophagus | ESCC | 4.01e-23 | 3.72e-01 | 0.0889 |
| 7703 | PCGF2 | P9T-E | Human | Esophagus | ESCC | 1.10e-04 | 1.05e-01 | 0.1131 |
| 7703 | PCGF2 | P10T-E | Human | Esophagus | ESCC | 1.68e-12 | 1.62e-01 | 0.116 |
| 7703 | PCGF2 | P11T-E | Human | Esophagus | ESCC | 4.66e-09 | 3.71e-01 | 0.1426 |
| 7703 | PCGF2 | P12T-E | Human | Esophagus | ESCC | 2.02e-43 | 7.26e-01 | 0.1122 |
| 7703 | PCGF2 | P15T-E | Human | Esophagus | ESCC | 4.53e-28 | 6.62e-01 | 0.1149 |
| 7703 | PCGF2 | P16T-E | Human | Esophagus | ESCC | 1.78e-25 | 4.69e-01 | 0.1153 |
| 7703 | PCGF2 | P20T-E | Human | Esophagus | ESCC | 5.79e-05 | 1.22e-01 | 0.1124 |
| 7703 | PCGF2 | P21T-E | Human | Esophagus | ESCC | 2.54e-13 | 2.01e-01 | 0.1617 |
| 7703 | PCGF2 | P22T-E | Human | Esophagus | ESCC | 1.61e-05 | 1.01e-01 | 0.1236 |
| 7703 | PCGF2 | P23T-E | Human | Esophagus | ESCC | 9.55e-08 | 2.93e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003461412 | Liver | HCC | cellular response to reactive oxygen species | 102/7958 | 155/18723 | 3.70e-09 | 9.89e-08 | 102 |
| GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
| GO:00165742 | Liver | HCC | histone ubiquitination | 37/7958 | 47/18723 | 4.37e-07 | 7.23e-06 | 37 |
| GO:00703011 | Liver | HCC | cellular response to hydrogen peroxide | 66/7958 | 98/18723 | 5.74e-07 | 9.07e-06 | 66 |
| GO:0010390 | Liver | HCC | histone monoubiquitination | 23/7958 | 29/18723 | 5.86e-05 | 5.38e-04 | 23 |
| GO:000651311 | Liver | HCC | protein monoubiquitination | 44/7958 | 67/18723 | 1.08e-04 | 9.22e-04 | 44 |
| GO:003352211 | Liver | HCC | histone H2A ubiquitination | 20/7958 | 26/18723 | 3.82e-04 | 2.61e-03 | 20 |
| GO:0035518 | Liver | HCC | histone H2A monoubiquitination | 13/7958 | 17/18723 | 4.77e-03 | 2.02e-02 | 13 |
| GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
| GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
| GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
| GO:000030220 | Oral cavity | OSCC | response to reactive oxygen species | 143/7305 | 222/18723 | 1.32e-14 | 7.88e-13 | 143 |
| GO:004254219 | Oral cavity | OSCC | response to hydrogen peroxide | 101/7305 | 146/18723 | 1.30e-13 | 6.66e-12 | 101 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:003459920 | Oral cavity | OSCC | cellular response to oxidative stress | 173/7305 | 288/18723 | 2.90e-13 | 1.43e-11 | 173 |
| GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:00183944 | Oral cavity | OSCC | peptidyl-lysine acetylation | 108/7305 | 169/18723 | 4.55e-11 | 1.45e-09 | 108 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PCGF2 | SNV | Missense_Mutation | novel | c.291N>A | p.Phe97Leu | p.F97L | P35227 | protein_coding | deleterious(0.04) | probably_damaging(0.945) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCGF2 | SNV | Missense_Mutation | rs746734324 | c.500N>A | p.Arg167Gln | p.R167Q | P35227 | protein_coding | tolerated(0.51) | benign(0.037) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| PCGF2 | SNV | Missense_Mutation | novel | c.871N>A | p.Gly291Arg | p.G291R | P35227 | protein_coding | tolerated(0.49) | probably_damaging(0.996) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| PCGF2 | deletion | Frame_Shift_Del | novel | c.228_232delAGACA | p.Gln76HisfsTer11 | p.Q76Hfs*11 | P35227 | protein_coding | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| PCGF2 | SNV | Missense_Mutation | rs746734324 | c.500N>A | p.Arg167Gln | p.R167Q | P35227 | protein_coding | tolerated(0.51) | benign(0.037) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PCGF2 | SNV | Missense_Mutation | novel | c.82N>A | p.Ala28Thr | p.A28T | P35227 | protein_coding | deleterious(0.02) | possibly_damaging(0.672) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCGF2 | SNV | Missense_Mutation | novel | c.278N>A | p.Arg93Gln | p.R93Q | P35227 | protein_coding | deleterious(0.01) | benign(0.109) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PCGF2 | SNV | Missense_Mutation | novel | c.82G>A | p.Ala28Thr | p.A28T | P35227 | protein_coding | deleterious(0.02) | possibly_damaging(0.672) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCGF2 | SNV | Missense_Mutation | rs779878626 | c.346N>A | p.Glu116Lys | p.E116K | P35227 | protein_coding | tolerated(0.05) | benign(0.18) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PCGF2 | SNV | Missense_Mutation | novel | c.790C>T | p.Pro264Ser | p.P264S | P35227 | protein_coding | tolerated(0.96) | benign(0.01) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |